Prediction: This Stock Could Double Over the Next 5 Years

Axe Cap view

Viking Therapeutics: A High-Risk Bet with Big Potential

Viking’s new obesity drug could reshape its growth story if clinical trials hold up.

Viking Therapeutics (VKTX) just raised $500 million to push its weight loss drug VK2735 through trials. The obesity treatment market is booming, forecasted to reach $77 billion by 2030, and even a small slice could double Viking’s current $4 billion value. That said, this isn’t a steady blue-chip; clinical trial setbacks can wipe out gains fast. The technology is promising—an injectable treatment followed by oral maintenance could disrupt how obesity drugs are sold. But biotech is binary: either the drug passes rigorous approval hurdles or it stumbles badly. In South Africa, we don’t have a direct equivalent listed on the JSE, so if you want exposure, watching USD/ZAR makes sense since global biotech risk sentiment often boosts or weakens the rand. Remember, patient capital is essential here because volatility will be high. this is just our opinion and not financial advice